Singapore-based health technology company Respiree is set to partner with Roche Diagnostics to launch pilot programmes across the Asia Pacific (APAC) region in the first quarter of 2025.
The pilot programmes will combine Roche’s cobas pulse system with Respiree’s vital sign monitoring solution to provide a simplified approach to patient monitoring.
The combined solution is expected to integrate machine learning models in future to predict clinical deterioration using historical data with risk scores at the bedside.
It allows healthcare professionals to register patients to Respiree’s connected devices in real-time and monitor historical data and potential deterioration directly at the patient’s bedside.
Also, the integrated solution eliminates the need to return to workstations or medical carts, as well as, simultaneously measure vital signs and blood sugar.
Respiree founder and CEO Gurpreet Singh said: “The use of Respiree with the cobas pulse system has tremendous potential to enhance clinical workflows.
“Nurses can administer devices and view historical vitals in real-time without the need for centralised workstations, providing immediate bedside insights into patient progress.
“Additionally, nurses can automate the extraction and measurement of vitals from connected devices almost instantaneously, removing the need for manual scanning and measurements.”
According to Respiree, existing patient monitoring involves nurses managing patients from centralised workstations, monitoring vitals and biomarkers, and manually collecting vitals.
The process can be ineffective with limited workstations, multiple workflows, increased patient volumes, and shortages in nursing staff.
Roche’s cobas pulse system is a point-of-care (POC) diagnostic device that features digital health applications based on the Android operating system.
It enables real-time administration and visualisation, without needing centralised workstations.
Respiree’s solution measures multiple biometrics, including pulse rate, oxygen saturation, respiratory rate, temperature, tidal depth, and inhalation-to-exhalation ratios.
The Respiree and cobas pulse solutions will simplify clinical workflows and enhance diagnostic and monitoring capabilities to improve patient outcomes, said the health technology company.
